Accuracy and technical characteristics of CYP2C19 point of care tests: a systematic review.
Eve TomlinsonChris CooperHayley E JonesCatalina Lopez ManzanoRachel PalmerJoe CarrollAyman SadekNicky J WeltonMariska M G LeeflangPenny F WhitingPublished in: Pharmacogenomics (2024)
Aim: To assess the accuracy and technical characteristics of CYP2C19 point of care tests (POCTs). Patients & methods: Systematic review of primary studies, in any population or setting, that evaluated POCTs for detecting CYP2C19 loss of function (LOF) alleles. Results: Eleven studies provided accuracy data (eight Spartan; one Genomadix Cube; one GMEX; one Genedrive). The POCTs had very high sensitivity and specificity for the alleles they tested for. Twenty-two studies reported technical characteristics: POCTs were easy to operate and provided results quickly. Limited data were reported for test failure rate and cost. Conclusion: CYP2C19 POCTs may be a useful alternative to laboratory-based testing to guide antiplatelet therapy. Further data are required on accuracy (GMEX; Genedrive), test failure and cost (all POCT).
Keyphrases
- antiplatelet therapy
- systematic review
- electronic health record
- end stage renal disease
- case control
- big data
- acute coronary syndrome
- percutaneous coronary intervention
- ejection fraction
- newly diagnosed
- chronic kidney disease
- meta analyses
- randomized controlled trial
- peritoneal dialysis
- prognostic factors
- machine learning
- patient reported outcomes
- patient reported